First Trust Dorsey Wright Dynamic Focus 5 ETF FVC 深 滬
等待開盤 11-26 09:30:00 美东时间
35.978
+0.213
+0.60%
華盛通- 最 高35.978
- 今 開35.76
- 成交量 1989股
- 最 低 35.76
- 昨 收 35.765
- 總市值 1.30亿
- 52周最高 37.7887
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 31.4061
- 委 比 -2.08%
- 總股本 360.00万
- 歷史最高 38.5712
- 量 比 0.26
- 振 幅 0.61%
- 歷史最低 12.548
- 每 手 1
- 風險率 1.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tvardi Therapeutics Said Preliminary Data From Phase 2 REVERT Trial of TTI-101 In Idiopathic Pulmonary Fibrosis Show That The Study Did Not Meet Its Goals
The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was designed to assess
10-13 19:32
十多年来首款！FDA批准突破性小分子疗法
10月8日，据药明康德官微消息称，美国FDA宣布，批准勃林格殷格翰（Boehringer Ingelheim）所开发的小分子片剂Jascayd（nerando...
10-08 15:53
First Trust Dorsey Wright Dynamic Focus 5 ETF declares $0.2262 dividend
First Trust Dorsey Wright Dynamic Focus 5 ETF (NASDAQ:FVC) declares $0.2262/share quarterly dividend. Payable Sept. 30; for shareholders of record Sept. 25; ex-div Sept. 25. See FVC Dividend Scorecard...
09-25 20:56
GRI Bio Reports Interim 6-Week Lung Function Results From Ongoing Phase 2a Study Evaluating GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis; Phase 2a Study Fully Enrolled; Topline Data On Track For Q3 2025
No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker dataPhase 2a study fully enrolled; Topline data on track for Q3 2025Currently available treatments for IPF
09-11 20:47
Why Is United Therapeutics Stock Rallying On Tuesday?
United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.
09-02 22:59
United Therapeutics' TETON-2 Study Of Nebulized Tyvaso (Treprostinil) Inhalation Solution For Idiopathic Pulmonary Fibrosis Met Its Primary Efficacy Endpoint Of Demonstrating Improvement In Absolute Forced Vital Capacity Relative To Placebo
Tyvaso demonstrated superiority over placebo for the change in absolute FVC by 95.6 mL (Hodges-Lehmann estimate, p <0.0001) from baseline to week 52 in patients with IPF. Benefits of Tyvaso were observed across all
09-02 19:01
Pliant Therapeutics Discontinues Development Of Bexotegrast In Idiopathic Pulmonary Fibrosis After BEACON-IPF Phase 2b/3 Clinical Trial Review
Bexotegrast development in IPF discontinuedClinical oncology program and early-stage programs continueRecent workforce and operational changes align with next stepsSOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE
06-28 04:12
First Trust Dorsey Wright Dynamic Focus 5 ETF declares $0.2677 dividend
First Trust Dorsey Wright Dynamic Focus 5 ETF (NASDAQ:FVC) declared $0.2677/share quarterly dividend. Payable June 30; for shareholders of record June 26; ex-div June 26. See FVC Dividend Scorecard, Y...
06-27 01:48
First Trust Dorsey Wright Dynamic Focus 5 ETF declares $0.139 dividend
First Trust Dorsey Wright Dynamic Focus 5 ETF (NASDAQ:FVC) declares $0.139/share quarterly dividend. Forward yield 1.61% Payable March 28; for shareholders of record March 22; ex-div March 21. See FVC...
2024-03-27 23:25
